Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study) by Yu Qiang Soh, Zheng Xian Thng, Wei Kiong Ngo, Colin S Tan, Tock Han Lim, Louis W Lim, Augustinus Laude, Darren Choy, Wen Jun Song, Helen Fang Mi, Koh Lilian, Jacob Yu Hang Chin, Karen Jhi Wen Chia, Issac Too, Nicola Y Gan, Rajesh Rajagopalan

Get full text

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials by Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Srinivas R. Sadda, MD, Colin S. Tan, FRCOphth, FRCSEd (Ophth), Stela Vujosevic, MD, PhD, Sascha Fauser, MD, Kara Gibson, PhD, Carl Glittenberg, MD, Nancy Holekamp, MD, FASRS, Ben Lanza, PhD, Andreas Maunz, PhD, Jeffrey R. Willis, MD, PhD, Rishi P. Singh, MD

Get full text